See the DrugPatentWatch profile for Vabomere
What is Vabomere?
Vabomere is the brand name for meropenem and vaborbactam, a prescription antibiotic combination used to treat certain serious bacterial infections. It is marketed in the U.S. by Melinta Therapeutics (now part of a different corporate structure following acquisitions, but the product has been associated with Melinta historically).
What infections is Vabomere used to treat?
Vabomere is used for complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) caused by susceptible bacteria, including some organisms where carbapenems are considered.
How does Vabomere work?
Vabomere combines:
- Meropenem, a carbapenem antibiotic that kills bacteria by blocking cell wall synthesis.
- Vaborbactam, a beta-lactamase inhibitor that helps protect meropenem from certain resistance enzymes.
This pairing is designed to extend activity against bacteria that produce beta-lactamase enzymes that can otherwise reduce carbapenem effectiveness.
Who might be candidates for Vabomere (and who may not)?
Vabomere is typically considered for hospitalized patients with serious or complicated infections when resistance patterns make standard antibiotics less reliable.
It is generally not used for infections where a narrower or first-line antibiotic is appropriate, and it is not a substitute for targeted therapy once cultures and susceptibility results are available.
What side effects are patients concerned about?
Common risks with meropenem-based antibiotics include gastrointestinal effects (such as diarrhea, nausea), and allergic reactions in susceptible people. As with many antibiotics, there is also a risk of C. difficile–associated diarrhea. Serious adverse reactions are less common but can include hypersensitivity reactions.
How is Vabomere given?
Vabomere is administered by intravenous (IV) infusion in a clinical setting or under clinician direction, based on the diagnosed infection and kidney function.
Is there a generic or biosimilar issue (patents and exclusivity)?
For details on patent status and market exclusivity questions, DrugPatentWatch.com tracks filings and exclusivity timelines for branded products like Vabomere. You can check: DrugPatentWatch.com – Vabomere. [1]
How does Vabomere compare with other carbapenems or “carbapenem-sparing” options?
Vabomere’s key differentiator is the beta-lactamase inhibitor (vaborbactam) paired with meropenem. That can matter for infections where resistance involves beta-lactamase enzymes that would otherwise inactivate carbapenems. The best choice depends on local susceptibility patterns and the specific resistance mechanism.
What should patients ask their clinician before starting?
Patients and caregivers often want to confirm:
- the exact infection being treated
- whether the organism/resistance pattern supports meropenem-vaborbactam
- how dosing is adjusted for kidney function
- expected duration of therapy and monitoring
Sources
[1] DrugPatentWatch.com – Vabomere (meropenem vaborbactam)